On December 17, China’s National Medical Products Authority (NMPA) conditionally approved the listing...
Balversa (erdafitinib) for the Treatment of Urothelial Carcinoma
Balversa™ (erdafitinib) is one of the first fibroblast growth factor receptor (FGFR) kinase inhibitors to be approved for the treatment of locally advanced or metastatic urothelial carcinoma.
Lamzede (velmanase alfa) to Treat Alpha-Mannosidosis
Lamzede® (velmanase alfa) is one of the first enzyme replacement therapies indicated for the treatment of non-neurological symptoms of patients with mild-to-moderate alpha‑mannosidosis.
Revcovi for the Treatment of ADA-SCID
Revcovi (elapegademase-lvlr) is a PEGylated recombinant adenosine deaminase (rADA) enzyme indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in paediatric and adult patients.
Myalepta (metreleptin) for the Treatment of Lipodystrophy
Myalepta® (metreleptin) is a recombinant human leptin analogue indicated to treat complications of congenital or acquired generalised lipodystrophy.
February’s top news stories
Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.
Besremi (ropeginterferon alfa-2B) to Treat Polycythaemia Vera
Besremi® (ropeginterferon alfa-2B) is a mono-pegylated proline interferon indicated for the treatment of polycythaemia vera. It is one of the first of its kind to be approved for the condition.
Vemlidy (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for treatment of hepatitis B virus infection with compensated liver disease in adult patients.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.